Peter Bantock
Plus aucun poste en cours
Profil
Peter Bantock served as the Chief Commercial Officer at Accelerate Diagnostics, Inc. in 2013 and at Ventana Medical Systems, Inc. from 2011 to 2012.
Prior to that, he worked at Ventana Medical Systems, Inc. from 2003 to 2012.
He received his undergraduate degree from Rhodes University in 2009.
Anciens postes connus de Peter Bantock
| Sociétés | Poste | Fin |
|---|---|---|
Ventana Medical Systems, Inc.
 Ventana Medical Systems, Inc. Electronic Equipment/InstrumentsElectronic Technology Ventana Medical Systems, Inc. develops tissue-based diagnostic solutions. It designs and delivers medical diagnostic systems and slide-based cancer tests. Its products include absolute Eosinophil count (AEC) detection kit intended for laboratory use to identify targets by immunohistochemistry (IHC) in sections of formalin-fixed, paraffin-embedded tissue or frozen tissue on a BenchMark and BenchMark XT instrument and DISCOVERY XT research instrument that brings automation, reproducibility, and productivity to IHC and in situ hybridization (ISH) slide preparation and processing. The company was founded by Thomas M. Grogan in 1985 and is headquartered in Phoenix, AZ. | Corporate Officer/Principal | 01/10/2012 |
| ACCELERATE DIAGNOSTICS, INC. | Responsable des Ressources Humaines | - |
Formation de Peter Bantock
| Rhodes University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ACCELERATE DIAGNOSTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. Electronic Equipment/InstrumentsElectronic Technology Ventana Medical Systems, Inc. develops tissue-based diagnostic solutions. It designs and delivers medical diagnostic systems and slide-based cancer tests. Its products include absolute Eosinophil count (AEC) detection kit intended for laboratory use to identify targets by immunohistochemistry (IHC) in sections of formalin-fixed, paraffin-embedded tissue or frozen tissue on a BenchMark and BenchMark XT instrument and DISCOVERY XT research instrument that brings automation, reproducibility, and productivity to IHC and in situ hybridization (ISH) slide preparation and processing. The company was founded by Thomas M. Grogan in 1985 and is headquartered in Phoenix, AZ. | Electronic Technology |
